홈MCP워크벤치Skills
홈워크벤치알림마이페이지
llms.txt · MCP 가이드개인정보처리방침 · 이용약관 · 지원v1.8.3
  1. 홈
  2. /반응

Levodopa → Carbidopa

HRID 452338
인쇄

반응식

HRID 452338 반응식
C1C(C[C@H](N)C(O)=O)=CC(O)=C(O)C=1.C1C(C[C@H](N)C(O)=O)=CC(O)=C(O)C=1.[CH3:29][C@@:30]([NH:43][NH2:44])([C:40]([OH:42])=[O:41])[CH2:31][C:32]1[CH:33]=[CH:34][C:35]([OH:39])=[C:36]([OH:38])[CH:37]=1>>[CH3:29][C@@:30]([NH:43][NH2:44])([C:40]([OH:42])=[O:41])[CH2:31][C:32]1[CH:33]=[CH:34][C:35]([OH:39])=[C:36]([OH:38])[CH:37]=1
참가 물질실험 절차출처 및 근거반응 노트

참가 물질

3

반응물 2

HCID 6047LevodopaHCID 104778Carbidopa-levodopa mixt.

생성물 1

HCID 34359Carbidopa

실험 절차

The in vitro dissolution profile of levodopa-carbidopa extended release capsules (from Example 3E), containing 200 mg levodopa and 50 mg carbidopa was obtained under simulated gastric conditions. The dissolution tests were performed in 900 mL of a 0.1 N HCl-pH 1.2 solution in a USP II apparatus at a temperature of 37° C. The paddle speed was set at 50 rpm. Samples of dissolution media were collected at predetermined intervals and analyzed by HPLC. The dissolution profiles of levodopa and carbidopa obtained from HPLC analysis are shown in FIG. 13.

출처 및 근거

ORD 기록
ord-63192a2fe1f54bafafb08780368c4579
출처 데이터셋
uspto-grants-2013_07
DOI
10.6084/m9.figshare.5104873.v1
특허 번호
US08491929B2

반응 노트

이 페이지에서참가 물질실험 절차출처 및 근거반응 노트